

Curidium Medica Plc

("Curidium" or "the Company")

Strategic Review and Board Changes

London, UK, 23 July 2008, Curidium Medica plc, (LSE: CUR), the personalised medicine company focused on bringing the right drug to the right patient, today announced that Gosse B. Bruinsma M.D. is moving from chairman to the position of Non-Executive Director. Dr. Barry Porter, co-founder and currently Non-Executive Director, becomes Chairman, with immediate effect. Dr. Bruinsma has cited his other business obligations and Curidium's need for dedicated leadership at this important time as reasons for the strategic change.

Led by Dr Porter, Curidium has initiated a strategic review to maximise its commercial development opportunities. With the pharmaceutical industry's growing interest in personalised medicine the Company will ensure its intellectual property assets and strong balance sheet are fully utilised to deliver optimum value to shareholders.

Curidium will enhance its R&D activities, with the aim of fully leveraging its product portfolio in support of business development activities as the Company continues to receive positive feedback from customers on PsychINDx™: a diagnostic blood test that classifies patients with schizophrenia/bipolar disorder into different subgroups, which may result in the improved treatment of these patients.

Commenting on the reorganisation, Dr. Porter, Chairman, said: "On behalf of the Board, I would like to thank Gosse for his contribution and achievements during his time as Chairman. This is a very exciting time for Curidium; the regulators and leading drug companies are beginning to recognise the significant importance of personalised medicines and I believe the Company is well placed to capitalise on this in the near future."

-ENDS-

For further information:

Curidium Medica plc

Barry Porter, Chairman

+44 (0) 20 7554 5100

Rob Smith, Finance Director

+44 (0) 20 7554 5102

<http://www.curidium.com/>

FinnCap

Charles Cunningham

+44 (0) 20 7600 1658

<http://www.jmfinncapitalmarkets.com/>

Media enquiries:

Abchurch

Tel: +44 (0) 20 7398 7700

Heather Salmond / Stephanie Cuthbert / Simone Alves

Tel: +44 (0) 20 7398 7718

Tel: +44 (0) 20 7398 7728

stephanie.cuthbert@abchurch-group.com

www.abchurch-group.com

Notes to Editors

About Dr Barry Porter, Chairman, Curidium Medica Plc

Barry is a Director of Union Life Sciences and an Non-Executive Director of Inhibox Limited. Barry has almost thirty years of drug discovery experience working in the pharmaceutical industry. He was Chief Executive of ReOx Ltd, a biotechnology spin out from the University of Oxford which entered into a ground breaking co-development deal with a major international biopharmaceutical company in its first year of operations. Prior to these roles, Barry held senior positions at De Novo Pharmaceuticals, Pharmagene, now Asterand, Rhone-Poulenc Rorer and Glaxo Group Research. He gained his PhD from the University of California, San Diego followed by a post doctoral fellowship with Syntex in Palo Alto.

About Curidium Medica

Curidium is a personalised medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder, by targeting the right drug to the right patient subgroup.

Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterised by distinct underlying disease mechanisms potentially leading to the identification of:

1. Diagnostics for better identification and treatment within heterogeneous disease populations.
2. Improved therapies identified through novel drug targets.
3. Personalised medicines using companion diagnostics and targeted treatments.

Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas.

Curidium Medica plc © 2002-2008. All rights reserved.

Studio 10, Tiger House, Burton Street, London WC1H 9BY, United Kingdom.

Email: info@curidium.com Tel.: +44 (0)20 7554 5100, Fax: +44 (0)20 7383 2973